Visceral Adipose-Targeted Stack

Visceral adipose tissue is metabolically distinct from subcutaneous fat — more inflammatory, more strongly associated with cardiometabolic risk, and disproportionately responsible for the cardiovascular and hepatic consequences of overweight states. Most weight-loss interventions reduce visceral fat proportionally to overall fat loss, but two compounds on this site have specific visceral-fat biology: tesamorelin (FDA-approved for HIV-associated visceral adiposity, with the strongest visceral-fat-specific clinical dataset of any peptide), and tirzepatide (substantial visceral-fat reduction in SURMOUNT trials).

The pairing logic is straightforward: tirzepatide drives the broad weight-loss effect while tesamorelin targets the visceral compartment specifically. For users whose primary concern is visceral fat — central obesity with elevated cardiometabolic markers, NAFLD-spectrum liver findings, or metabolic syndrome features — the combination addresses the specific tissue that drives their risk profile.

The peer-reviewed literature on this combination is summarized below across two tiers — controlled human research (the highest standard) and preclinical / animal-model evidence.

• Does adding tesamorelin to tirzepatide produce additive visceral-fat reduction beyond tirzepatide alone?
• What is the optimal sequencing — concurrent or layered after weight-loss plateau on tirzepatide?
• Does the combination produce meaningful improvement in NAFLD-spectrum imaging endpoints over tirzepatide alone?
• What are the long-term cancer and glucose-tolerance outcomes of sustained combination use?

The Visceral Adipose-Targeted stack is a thoughtful combination for users whose primary concern is visceral fat and the cardiometabolic risk that follows from it. Both components have approved-grade individual evidence, the mechanistic complementarity is clean, and the framing — visceral fat as the clinically-relevant target — matches the actual biology better than overall-weight framings often do. Combination-specific Phase 3 evidence is the gap; for now, the framework is mechanistically defensible but extrapolated rather than directly validated.